Ernexa Therapeutics Inc. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for the quarter ending 2026-06-30 was $24.00K, a 48.94% decline year-over-year.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for the quarter ending 2026-03-31 was $96.00K, a 113.33% increase year-over-year.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for the quarter ending 2025-12-31 was $0.00.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for the quarter ending 2025-09-30 was $48.00K.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for fiscal 2025 was $141.00K, a 513.04% increase from fiscal 2024.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for fiscal 2024 was $23.00K.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for fiscal 2015 was $1.00K, a 99.59% decline from fiscal 2014.
- Ernexa Therapeutics Inc. stock issued during period, value, issued for services for fiscal 2014 was $242.00K, a 520.51% increase from fiscal 2013.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2026-06-30 | $24.00K 10-Q · filed 2026-08-06 | $168.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $96.00K 10-Q · filed 2026-05-11 | $191.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $141.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $48.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $47.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $45.00K 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $23.00K 10-K · filed 2026-03-13 | |
| 2015-12-31 | $1.00K 10-K · filed 2017-03-09 | |
| 2014-12-31 | $242.00K 10-K · filed 2016-03-15 | |
| 2013-12-31 | $39.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |